Conferences - Results from #220

Viewing 221-240 of 11869 articles

ESMO 2024: Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically for High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC): Interim Analysis of a Phase I Study

ESMO 2024: First Preliminary Results of Artificial Intelligence Generated Treatment Recommendations for Urothelial Cancer Based on Multidisciplinary Cancer Conferences from the KITTU Project

ESMO 2024: Hematologic Impact of [177Lu]Lu-PSMA-617 Versus ARPI Change in Patients with Metastatic Castration-Resistant Prostate Cancer in PSMAfore

ESMO 2024: Targeting Epigenetic Pathways

ESMO 2024: STAR-EV: Stereotactic Treatment with Neoadjuvant Radiotherapy and Enfortumab Vedotin: A Phase I/II Study for Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer

ESMO 2024: Similar Genetic Profile in Early and Late Stage Urothelial Tract Cancer Suggests That Early Genomic Testing Bears the Potential of Timely Personalized Treatment in Clinical Trials

ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE

ESMO 2024: A Phase II Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder

ESMO 2024: Invited Discussant: RAPSON: Open-Label, Multicenter Randomized Trial of Radium-223 and Adding Metformin to ADT for Patients with mHSPC

ESMO 2024: Invited Discussant: Phase 3 ARANOTE Trial, Phase 3 Evaluation of Transdermal Estradiol vs LHRH Agonists and Ancillary Study of the PEACE-1

ESMO 2024: Systemic Treatment Options

ESMO 2024: Is There a Role for Radiation Therapy in Advanced RCC?

ESMO 2024: Efficacy and Safety of Darolutamide plus ADT in Patients with mHSPC from the Phase 3 ARANOTE Trial

ESMO 2024: Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase 3 Trial

ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2024: INSPIRE: Phase 2 Trial of Nivolumab 3mg/kg and Ipilimumab 1mg/kg in Molecularly Selected Patients with mCRPC

ESMO 2024: RAPSON: Open-Label, Multicenter Randomized Trial of Radium-223 -> Docetaxel Versus Docetaxel -> Radium-223 Sequence in mCRPC with Prospective Biomarker Evaluation

ESMO 2024: The Role of Cytoreductive Nephrectomy in the Immunotherapy Era

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer

7
8
9
10
11
12
13
14
15
16